Discover dosing and administration for ALOXI® (palonosetron HCl)       View in browser         Full Prescribing Information       Important Safety Information Physician Resources   Important Safety Information Physician Resources      Patient Resources         Indication     ALOXI® injection is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and the prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.       Important Safety Information       CONTRAINDICATIONS       ALOXI is contraindicated in patients known to have hypersensitivity to the drug or any of its components       Please see below for additional Important Safety Information.       ALOXI: Dosing and Administration       A single 0.25 mg IV dose of ALOXI should be administered approximately 30 minutes prior to chemotherapy1 Infuse over 30 seconds1 Can be used with other antiemetic agents, including NK1 RAs and/or dexamethasone1 ALOXI can be given with each cycle of chemotherapy1       ALOXI has a 40-hour half-life, and has been shown to have a strong binding affinity to the 5-HT3 receptor1,2∗     * The correlation between these pharmacological data and clinical efficacy has not been established. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the small intestine and that the released serotonin then activates 5-HT3 receptors in the brain to initiate the vomiting reflex.1,3             Important Safety Information (continued)       WARNINGS AND PRECAUTIONS       Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other 5-HT3 receptor antagonists   Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone, but particularly with the use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue ALOXI and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if ALOXI is used concomitantly with other serotonergic drugs       ADVERSE REACTIONS       In adults, the most commonly reported adverse drug reactions include headache (9%) and constipation (5%)       For more information about ALOXI, please see Full Prescribing Information.       References: 1. ALOXI® (palonosetron HCl) injection. Full Prescribing Information. 2. Schwartzberg L, Szabo S, Gilmore J, et al. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC). Curr Med Res Opin. 2011;27:837-845. 3. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs. 1998;55:173-189.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license. Distributed by Eisai Inc. under license of Helsinn Healthcare SA, Switzerland. Marketed by Eisai Inc. and Helsinn Therapeutics (U.S.), Inc.     Eisai, Inc. 1‌00 T‌ice B‌oulevard, W‌oodcliff L‌ake, N‌J 0‌7677 - (USA). Helsinn Therapeutics (U.S.), Inc. 1‌70 W‌ood A‌venue South, 5th Floor, Iselin, N‌J 0‌8830 - (USA). © 2017 Eisai Inc.     All rights reserved.      ALOX-US0305     0‌2/17